Pharmaceutical Business Review
Fine & Specialty Chemicals
Anonymous User | Login

Glycos Biotechnologies Produces Biochemicals In Pilot Plant Size Environment

Published: 10-Mar-2010

Glycos Biotechnologies, an emerging specialty chemicals company, said that it has produced lactic acid and advanced ethanol in a commercial size facility capable of producing up to 150,000 liters of chemicals.

GlycosBio has created a platform that can consume carbon from multiple non-sugar feedstock sources to produce a variety of chemical products. The approach not only eliminates the risk of a sugar-only based feedstock strategy but also provides product flexibility and a larger addressable market opportunity for producers.

Rich Cilento, CEO of Glycos Biotechnologies, said: “Replicating what has been accomplished in our lab now in a commercial setting, and at a larger scale, is a significant achievement for GlycosBio. Our work in the pilot plant will help the organization meet partner milestones related to the commercialization efforts we already have underway. In addition, the success of the pilot production validates the efficiency and ease-of-scale of GlycosBio’s technology in larger production systems and proves our economic models and the profit opportunities we can offer producers of chemicals and biofuels. With the pilot plant successfully operational we are now focused on engaging the marketplace to secure additional commercialization partnerships around the world.”

Paul Campbell, chief scientific officer of Glycos Biotechnologies, said: “By using our proprietary microbes and bioprocess technologies as an alternative to conventional petrochemical-based manufacturing processes, GlycosBio has invented a sustainable and cost-efficient approach to the production of next generation bio-products. Through the creation of biologically ‘balanced’ pathways inside the microbe we have been able to uniquely develop microorganisms that naturally produce the desired end-products.”

GlycosBio is focused on the production of specialty chemicals that can be used as building blocks for a wide range of applications including biodegradable and non-degradable plastics. In addition, other applications for GlycosBio’s chemicals include surfactants and fuels such as advanced ethanol. By bridging innovative metabolic engineering and efficient process design, GlycosBio discoveries will drive sustainable solutions for the world’s energy, chemicals, and materials problems.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Almac

Drug Development Solutions ...

Boehringer Ingelheim

Drug Substance and Drug Product Services ...

Cerbios-Pharma SA

High Quality & Reliable Services ...

CurTec

Producer & Manufacturer of Plastics Packaging ...

Cutting Edge Information

Pharmaceutical Business Intelligence Reports ...

IRIS Biotech

Peptide Synthesis and Pharmaceutical Intermediates ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CaseBase Management

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

SafetyBase Interchange

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

ClinicalBase Trial

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

Reliable Prediction of White Plasma Levels

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Kinetics and Metabolism

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Drug Safety Evaluation

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

No items to display

Suppliers Product News

Almac Completes Phase One of Its Expansion Plan to Pharma Services Facilities

New $15m facility will "meet growing business need for its integrated product development and commercial services."

Almac Completes £2 million Client Sponsored Investment Expanding Commercial Sacheting Capacity

Meeting our client partner's commercial need for additional sachet capacity, Almac completes a £2 million investment programme.

Almac's US Headquarters will Address Capacity Demand for Clinical Supplies

Huge increase in storage capacity for ambient, cold storage and controlled drugs.

Cerbios-Pharma SA Introduces a New Company Image and Website

Cerbios-Pharma SA is proud to announce the launch of the company's new image and website.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address